Back to discover

Protein / target

Tumor necrosis factor ligand superfamily member 4

Encoded byTNFSF4P23510Homo sapiensSwiss-Prot
UniProt: P23510Ensembl: ENSG00000117586HGNC: HGNC:11934NCBI Gene: 7292
Clinical-stage
Therapeutic maturity
2
Clinical candidates
Antibody-tractable
Druggability
Advanced Clinical
1
Research papers

Protein at a glance

Biological role

Tumor necrosis factor receptor superfamily binding

Strongest disease association

Asthma

Via encoding gene TNFSF4 · Genetic evidence · score 0.86

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Cytokine that binds to TNFRSF4.

View complete UniProt function annotation

Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production

Subcellular location

Membrane
Domains and Gene Ontology detail (48)

Domains & features

THD

Gene Ontology

  • Ccell surface
  • Cextracellular space
  • Cplasma membrane
  • Fcytokine activity
  • Fsignaling receptor binding
  • Ftumor necrosis factor receptor binding
  • Ftumor necrosis factor receptor superfamily binding
  • Pacute inflammatory response
  • Pcellular response to lipopolysaccharide
  • Pcellular response to prostaglandin E stimulus
  • Pdefense response to nematode
  • Pimmune response

183 aa · 21 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Immune signalling

  • ·Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production
  • ·cytokine activity
  • ·acute inflammatory response
  • ·immune response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TNFSF4

Gene-level evidence surfaced through the gene TNFSF4that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma
0.90Well supported

Genetic evidence dominant · Open Targets 0.56

Dermatitis, Atopic
0.85Well supported

Genetic evidence dominant · Open Targets 0.52

Lupus Erythematosus, Systemic
0.82Well supported

Genetic evidence dominant · Open Targets 0.59

Rhinitis, Allergic
0.79Well supported

Genetic evidence dominant · Open Targets 0.48

Arthritis, Rheumatoid
0.75Well supported

Genetic evidence dominant · Open Targets 0.46

View evidence synthesis (5)
AsthmaWell supported
0.90
agreement 0.79–1.00
Genetic75%Literature11%Clinical11%RNA expression3%

Open Targets aggregate 0.56 · 4 independent evidence families

Dermatitis, AtopicWell supported
0.85
agreement 0.74–0.95
Genetic58%Clinical40%Literature3%

Open Targets aggregate 0.52 · 3 independent evidence families

Lupus Erythematosus, SystemicWell supported
0.82
agreement 0.68–0.96
Genetic85%Literature15%Genetic literaturedup

Open Targets aggregate 0.59 · 2 independent evidence families · 1 not counted as duplicate

Rhinitis, AllergicWell supported
0.79
agreement 0.68–0.90
Genetic92%Clinical5%Literature3%

Open Targets aggregate 0.48 · 3 independent evidence families

Arthritis, RheumatoidWell supported
0.75
agreement 0.61–0.89
Genetic87%Literature13%

Open Targets aggregate 0.46 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Lupus Erythematosus, Systemic0.59
Asthma0.56
Dermatitis, Atopic0.52
Rhinitis, Allergic0.48
Arthritis, Rheumatoid0.46
Childhood onset asthma0.43
Respiratory Tract Diseases0.42
Hypersensitivity0.42
Venous Thrombosis0.41

Drug development

2 compounds recorded · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (2)
OXELUMABPhase 2
AMLITELIMABPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Strong

Advanced Clinical and GO CC high conf support this modality.

View underlying tractability evidence (3)
AB · Advanced ClinicalAB · GO CC high confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

OX40/OX40 ligand and its role in precision immune oncology.45 cites

Thapa B · Cancer metastasis reviews · 2024

Recent

OX40/OX40 ligand and its role in precision immune oncology.

Thapa B · Cancer metastasis reviews · 2024

Europe PMC papers linked directly to this protein.